Eugia Pharma has signed a voluntary sub-licensing agreement with Medicines Patent Pool to make and sell Nilotinib capsules, originally developed by Novartis, for chronic myeloid leukemia in 44 low and middle-income countries
Nifty Sensex on a Downtrend - Weekly Closing Report moneylife.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from moneylife.in Daily Mail and Mail on Sunday newspapers.
Shares of Aurobindo Pharma went up by 3% after the company announced that its subsidiary Eugia Pharma has signed a voluntary license with Medicines Patent Pool to create and market a generic version of Nilotinib Capsules. Aurobindo Pharmas wholly-owned subsidiary Eugia Pharma Specialities has entered a voluntary sublicensing agreement with Medicines Patent Pool to manufacture and market the drug in 44 low and middle-income countries for the treatment of chronic myeloid leukemia.
Eugia Pharma signs voluntary license with Medicines Patent Pool to develop and market generic version of Nilotinib Capsules equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.